Levocetirizine — How Dangerous It Is, Side Effects, and Consequences of Long-Term Use

EFFECTIVE | TOXIC

Names of Levocetirizine and Hidden Duplication of the Active Ingredient

The international nonproprietary name is levocetirizine; the Latin spelling is levocetirizine. Medicinal products usually contain levocetirizine dihydrochloride; less commonly, documentation may use the names levocetirizine hydrochloride, levocetirizine diHCl, and R-cetirizine. Levocetirizine is the active R-enantiomer of cetirizine, but this does not mean that the two medicines can be taken together: combining levocetirizine with cetirizine results in pharmacological duplication of H1-blocking activity. Dosage forms include 5 mg tablets, 2.5 mg tablets, and an oral solution or drops at a concentration of 0.5 mg/mL. The main brand names include Xyzal, Suprastinex, Glencet, Allerway, Zodak Express, Elcet, Levocetirizine-Teva, Levocetirizine-SZ, Levocetirizine-Vertex, Aleron, Cetrilev, L-Cet, Teczine, Vozet, and Zenaro. Combination products may contain levocetirizine together with montelukast, ambroxol, phenylephrine, or other components. The names of such combinations vary by country, so the composition should be checked under “active ingredients” rather than by the brand name. Xyzal formulations contain levocetirizine dihydrochloride in tablets and oral solution.

Why Levocetirizine Is Considered Harmless and Where the Real Risk Begins

Levocetirizine is often taken as an ordinary “allergy pill,” without associating it with daytime drowsiness, slowed reaction time, reduced concentration, fatigue, or difficulty urinating. Over-the-counter availability reinforces a false sense of safety and encourages repeated dosing, exceeding the daily dose, and simultaneous use of medicines containing cetirizine or levocetirizine under different brand names. The main everyday risk is not massive organ toxicity, which is characteristic of some other medicines, but central nervous system depression, impaired psychomotor function, and accumulation of the drug when kidney function is reduced. Alcohol, sleeping pills, tranquilizers, sedative herbal remedies, and other central nervous system depressants can make an otherwise usual dose clinically dangerous when driving, operating machinery, or in situations involving a risk of falls. A separate problem associated with long-term daily use is a rare but sometimes extremely intense generalized itching that develops several days after the medicine is discontinued.

Side Effects During the First Hours and Days of Treatment

The most common reactions in adults and adolescents are drowsiness, fatigue, dry mouth, pharyngitis, and symptoms of nasopharyngitis. Drowsiness may occur after the very first dose and may be accompanied by reduced attention, slower reaction time, and impaired coordination, even when the patient does not subjectively perceive a pronounced sedative effect. In children, fever, cough, nosebleeds, diarrhea, vomiting, constipation, and otitis have also been reported; in some children, agitation and restlessness may occur before drowsiness develops. Clinically significant reactions include urinary retention, palpitations, tachycardia, visual disturbances, tremor, dizziness, paresthesia, marked weakness, aggression, agitation, hallucinations, depressive symptoms, insomnia, and oculogyric crisis with involuntary deviation or rotation of the eyes. The EMA has considered a causal relationship between levocetirizine and oculogyration to be pharmacologically plausible. Life-threatening reactions include anaphylaxis, angioedema involving the face, tongue, or larynx, and severe cutaneous hypersensitivity reactions.

Consequences of Long-Term and Repeated Use

Levocetirizine does not cause classic drug dependence; however, when used daily for months or years, a functional reliance on the medicine may develop: after discontinuation, intense itching may appear that was not present before treatment began. In 2025, the FDA required a specific warning about this complication to be added. The FDA pharmacovigilance database identified 209 reports of itching after discontinuation of cetirizine or levocetirizine, including 27 cases associated with levocetirizine and two cases involving use of both medicines. The reaction usually began within several days after discontinuation; most patients had taken the medicine for more than three months, although individual cases occurred after less than one month of use. The itching could be generalized and severe enough to disrupt sleep, work, and everyday activities. In most patients, it decreased after the medicine was restarted, and in some patients after a subsequent gradual dose reduction, although no standard evidence-based treatment regimen has yet been established. In chronic kidney disease, repeated doses may accumulate, increasing drowsiness and other adverse reactions. Therefore, the absence of noticeable complications during the first few weeks does not guarantee that problems will not arise during months of use or after discontinuation.

Contraindications and High-Risk Groups

Levocetirizine is contraindicated in patients with known hypersensitivity to the drug itself, cetirizine, or any component of the dosage form, because repeated exposure may cause urticaria, angioedema, or anaphylaxis. The drug is contraindicated in end-stage renal failure with a creatinine clearance below 10 mL/min and in patients undergoing hemodialysis: levocetirizine is eliminated predominantly by the kidneys and is practically not removed by dialysis. In children with impaired renal function, the drug is contraindicated in age groups for which a safely reduced dose cannot be selected. In adults with moderate or severe impairment of renal function, both the dose and the dosing frequency must be reduced. In elderly patients, a normal blood creatinine concentration does not always indicate preserved clearance, so a standard dose may be excessive. Prostatic hyperplasia, neurogenic bladder, spinal cord injury, and other conditions associated with impaired urinary outflow increase the risk of acute urinary retention. For patients who drive, work at height, or operate hazardous machinery, the drug may be dangerous because reaction impairment can occur without being obvious.

Dangerous Drug and Everyday Combinations

Combining levocetirizine with alcohol is highly undesirable: their effects may add together, worsening attention, drowsiness, and impaired coordination. A similar risk occurs when it is used together with benzodiazepines, sleeping pills, sedating antipsychotics, opioids, pregabalin, gabapentin, first-generation allergy medicines, and other agents that depress the central nervous system. Sedative herbal preparations, including valerian, motherwort, hops, kava, and passionflower, may also increase drowsiness; the extent of the interaction depends on the dose and product composition. Ritonavir can increase systemic exposure to cetirizine, so clinical assessment of tolerability is necessary with analogous combinations involving levocetirizine. Theophylline may reduce the total clearance of the related drug cetirizine, which is especially important in patients with impaired kidney function. Food has not been shown to have a clinically significant effect on the overall absorption of levocetirizine, although fatty food may delay the time to peak concentration. Nicotine and caffeine do not neutralize the sedative effect and may only subjectively mask fatigue. Hidden duplication occurs when levocetirizine, cetirizine, and combination products containing levocetirizine are used at the same time; such a regimen does not turn one tablet into “stronger allergy treatment,” but it does increase the dose burden and the likelihood of side effects.

Patient Errors When Using Levocetirizine

A typical mistake is taking another tablet because nasal congestion or a rash has not disappeared within an hour. Levocetirizine blocks H1 receptors, but it does not eliminate all mechanisms of inflammation and is not expected to completely control severe rhinitis, bronchial obstruction, angioedema, or chronic urticaria of unknown origin. Increasing the dose without reassessing the diagnosis raises the likelihood of drowsiness and overdose but does not address the reason for the lack of effect. Equally dangerous are taking different “anti-allergy” medicines containing the same substance in the morning and evening, giving an adult tablet to a child, measuring oral solution with a household spoon, and continuing the standard dosage after kidney function has declined. Alcohol taken after an evening dose is often perceived as acceptable because levocetirizine is a second-generation antihistamine, but the degree of sedation in an individual patient cannot be predicted in advance. Long-term self-treatment may mask an allergen, a drug reaction, a parasitic disease, autoimmune urticaria, or another cause of itching. Abrupt discontinuation after months of daily use may cause such severe itching that the patient mistakenly interprets it as a “return of the allergy” and begins taking the medicine again without control.

Levocetirizine Overdose and Poisoning

A precise universal toxic dose for humans has not been established, so it is incorrect to rely on a supposed number of tablets after which “poisoning begins.” In adults, exceeding the dose usually causes marked drowsiness, lethargy, reduced attention, and impaired coordination. In children, paradoxical agitation, motor restlessness, and irritability may occur during the first hours and may later be replaced by drowsiness. Even a relatively small excess dose may become dangerous in renal failure, old age, with simultaneous alcohol use, sedative medicines, or an error in calculating a pediatric dose. Hidden overdose can occur after taking another tablet, using drops and tablets simultaneously, combining levocetirizine with cetirizine, or using several combination products at once. There is no specific antidote. Treatment is symptomatic and supportive; hemodialysis does not provide effective removal of levocetirizine. After a substantial overdose, one should not wait for deep sleep, impaired consciousness, or breathing problems to develop: early medical assessment is necessary to monitor neurological status, respiration, hemodynamics, concomitant substances, and kidney function.

The materials have been prepared according to the structure of the pharmacological article: after the overdose section, the choice of a herbal alternative must be based only on the provided medicines, extracts, and links.

A Safe Integrative Alternative to Levocetirizine

As a basic systemic alternative for a mild or moderate stable allergic condition, “Allergy Mixture, Capsules LH” may be considered. Unlike levocetirizine, which competitively blocks peripheral H1 receptors and rapidly reduces histamine-dependent symptoms, this multi-component herbal preparation is aimed at broader correction of allergic inflammation. It should not automatically be considered equivalent in speed of action: in acute urticaria, intense generalized itching, or a rapidly progressing reaction, levocetirizine acts more predictably, whereas the herbal regimen is better suited to course-based therapy for a stable condition. In a pronounced IgE-dependent phenotype, Kra Chai Dam may be added to the basic regimen as a mechanism-oriented component aimed at reducing IgE–FcεRI–Syk-dependent activation and degranulation of mast cells. In leukotriene-dependent inflammation, persistent mucosal edema, or allergy combined with a bronchial component, the use of Boswellia serrata is justified; its boswellic acids are being studied as inhibitors of the 5-lipoxygenase pathway. In a predominantly nasal phenotype, “Rhinitis and Rhinosinusitis Mixture, Capsules LH” and the topical oil-based herbal mixture ABP-153 are used; the ABP-153-D variant contains DMSO and requires separate assessment of mucosal tolerability. Pinellia ternata has a distinct role in cough, bronchial hyperreactivity, eosinophilic inflammation, and mucus hypersecretion: experimental data show that Pinellia ternata extracts may reduce eosinophilic infiltration, airway hyperreactivity, and mucus production, but these findings cannot be unconditionally equated with the results of large clinical trials. In confirmed Th2/eosinophilic asthma, the specialized “Bronchial Asthma Type 2, Capsules LH” mixture is used, while in bronchial obstruction with thick, difficult-to-expectorate sputum, the “Asthma with Tenacious Sputum” bolus is used. These products are not emergency treatments for anaphylaxis, laryngeal edema, or a severe asthma attack. In an unstable condition, replacement of levocetirizine and basic anti-asthma therapy should be undertaken only after clinical assessment.

The Real Effectiveness of Levocetirizine and Prescribing Errors

Levocetirizine is genuinely effective for histamine-dependent symptoms of seasonal and perennial allergic rhinitis: sneezing, rhinorrhea, nasal itching, lacrimation, and itchy eyes. It also reduces wheals and itching in urticaria. Its effect begins approximately within the first hour and lasts for about 24 hours; in controlled studies, the drug was superior to placebo in reducing nasal and ocular symptoms. Levocetirizine does not eliminate the allergen, restore the mucosal barrier, treat infectious rhinosinusitis, or control all mediators of chronic allergic inflammation. It also does not replace epinephrine in anaphylaxis, an inhaled bronchodilator in bronchospasm, or basic anti-inflammatory asthma therapy. Common prescribing errors include using the drug for any nasal congestion without distinguishing between allergic, infectious, vasomotor, and drug-induced rhinitis; unjustifiably extending treatment for many months without reassessment; ignoring reduced kidney function; prescribing cetirizine and levocetirizine simultaneously; and attempting to treat cough, bronchial obstruction, or chronic rhinosinusitis with an antihistamine when histamine is far from the only factor involved in their pathogenesis. A tablet may suppress a symptom effectively, but a suppressed symptom does not mean that the disease itself has been cured.

Safety Monitoring During Treatment

With short-term use in a patient with preserved kidney function, routine laboratory tests are generally not required. Drowsiness, fatigue, dizziness, impaired attention, unusual agitation, palpitations, visual disturbances, and difficulty urinating should be monitored. Before starting a long-term course, as well as in elderly patients and in those with chronic kidney disease, diabetes mellitus, arterial hypertension, or urinary tract disorders, blood creatinine and estimated glomerular filtration rate should be assessed. Levocetirizine is eliminated predominantly by the kidneys, so reduced renal clearance increases drug exposure and requires adjustment of the dosing regimen. Swelling of the lips, tongue, face, or larynx, difficulty breathing, generalized urticaria with systemic symptoms, loss of consciousness, severe confusion, seizures, severe urinary retention, or persistent involuntary deviation of the eyes require immediate discontinuation and emergency medical care. After stopping long-term daily use, the patient should be monitored for the appearance of new generalized itching, especially if it was not present before treatment began. Waiting while angioedema or respiratory failure is progressing is dangerous because the airways may become rapidly obstructed; taking levocetirizine again on one’s own in such a situation may temporarily alter skin symptoms but will not stop systemic anaphylaxis.

Proper Discontinuation of Levocetirizine

After a short course, levocetirizine can usually be stopped immediately: the drug does not cause a classic dependence syndrome, and there is no mandatory standard tapering regimen. However, after daily use for several months or years, abrupt discontinuation may be accompanied by rare but severe generalized itching that begins within several days and may significantly disrupt sleep and everyday activities. In May 2025, the FDA required this complication to be added to the prescribing information for cetirizine and levocetirizine. According to pharmacovigilance data, symptoms decreased in some patients after restarting the drug and were then controlled with a slower dose reduction, but no universal evidence-based discontinuation regimen has yet been established. With long-term use, it is reasonable to discuss discontinuation in advance and distinguish post-drug itching from recurrence of the original allergy. Missing one dose usually does not require doubling the next dose. The return of rhinitis or urticaria after discontinuation does not always indicate a withdrawal syndrome: it may reflect continued exposure to the allergen, an undiagnosed disease, or inadequate control of the underlying inflammatory process.

A Reasonable Approach to Treatment

Levocetirizine is justified when a rapid and predictable reduction of histamine-dependent itching, sneezing, rhinorrhea, lacrimation, or urticarial wheals is required. Its advantages are a rapid effect, convenient once-daily dosing, and confirmed clinical efficacy. Its limitations are symptomatic action, possible drowsiness, dependence of dosing on kidney function, and the risk of severe itching after discontinuation following long-term daily use. In a mild or moderate stable allergic condition, therapy may gradually be shifted toward “Allergy Mixture, Capsules LH” with the addition of agents according to the specific phenotype: Kra Chai Dam for IgE-dependent mast cell activation, Boswellia serrata for leukotriene-dependent inflammation, a nasal regimen and ABP-153 for rhinitis and rhinosinusitis, and Pinellia ternata for cough, hyperreactivity, and mucus hypersecretion. In severe urticaria, anaphylaxis, progressive angioedema, or unstable asthma, herbal preparations must not delay necessary standard treatment. The goal of an integrative approach is not the mechanical replacement of one tablet with a collection of bottles, but a reduction in polypharmacy, sedative burden, and chronic suppression of symptoms without addressing the leading mechanism of the disease.

If you have any questions about the topic of this article, you can ask a clinical pharmacologist in the comments or make an appointment via the link: https://asiabiopharm.com/konsultaciii/